MedTrace Logo

Effective Phaco Time and Endothelial Cell Loss When Using Veritas

NCT07176416 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-10-09

No results posted yet for this study

Summary

This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.

Conditions

  • Cataract

Interventions

DEVICE

Veritas Vision System

Veritas Vision System

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Aloha Vision Consultants

    lead OTHER

Principal Investigators

  • Carlton Yuen, MD · Aloha Vision Consultants

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-03
Primary Completion
2026-10-01
Completion
2026-10-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07176416 on ClinicalTrials.gov